ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3027% below fair value
$13.56−0.07 (-0.51%)
Close on Nov 18, 2026Market cap $3.04BP/E 19.4Yield –
ADMA Biologics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
ADMA Biologics's free cash flow for the twelve months ending Jun 30, 2026 was $116.47M, up 77.1% year over year. For fiscal 2025 it was $27.82M, down 74.8% from the year before. The highest annual figure on record is $110.45M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.82M | -74.8% |
| FY2024 | Dec 31, 2024 | $110.45M | +2641.3% |
| FY2023 | Dec 31, 2023 | $4.03M | – |
| FY2022 | Dec 31, 2022 | -$73.42M | – |
| FY2021 | Dec 31, 2021 | -$125.88M | – |
| FY2020 | Dec 31, 2020 | -$114.73M | – |
| FY2019 | Dec 31, 2019 | -$80.01M | – |
| FY2018 | Dec 31, 2018 | -$64.77M | – |
| FY2017 | Dec 31, 2017 | -$39.95M | – |
| FY2016 | Dec 31, 2016 | -$18.34M | – |
| FY2015 | Dec 31, 2015 | -$15.44M | – |
| FY2014 | Dec 31, 2014 | -$17.03M | – |
| FY2013 | Dec 31, 2013 | -$11.08M | – |
| FY2012 | Dec 31, 2012 | -$7.02M | – |
| FY2011 | Dec 31, 2011 | -$1.43M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $27.28M | +45.8% |
| Q1 FY2026 | Mar 31, 2026 | $55.71M | – |
| Q4 FY2025 | Dec 31, 2025 | $34.56M | -27.2% |
| Q3 FY2025 | Sep 30, 2025 | -$1.08M | -104.5% |
| Q2 FY2025 | Jun 30, 2025 | $18.72M | -57.1% |
| Q1 FY2025 | Mar 31, 2025 | -$24.38M | – |
| Q4 FY2024 | Dec 31, 2024 | $47.46M | +189.4% |
| Q3 FY2024 | Sep 30, 2024 | $23.97M | +113.5% |
| Q2 FY2024 | Jun 30, 2024 | $43.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.57M | – |
| Q4 FY2023 | Dec 31, 2023 | $16.40M | – |
| Q3 FY2023 | Sep 30, 2023 | $11.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.93M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.67M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.67M | – |
| Q2 FY2022 | Jun 30, 2022 | -$16.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.86M | – |
| Q4 FY2021 | Dec 31, 2021 | -$37.14M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$36.74M | – |
| Q1 FY2021 | Mar 31, 2021 | -$35.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$35.82M | – |
| Q3 FY2020 | Sep 30, 2020 | -$26.74M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.45M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.72M | – |
| Q4 FY2019 | Dec 31, 2019 | -$21.25M | – |
| Q3 FY2019 | Sep 30, 2019 | -$26.09M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.27M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.40M | – |
| Q4 FY2018 | Dec 31, 2018 | -$19.61M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.77M | – |
| Q2 FY2018 | Jun 30, 2018 | -$15.41M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.98M | – |
| Q4 FY2017 | Dec 31, 2017 | -$15.37M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.31M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.87M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.40M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.62M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.69M | – |
See a number that looks wrong?